Evolus, Inc. (EOLS) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 16, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the EOLS SEC filings page.
Evolus, Inc. (EOLS) reported $316.5M in revenue over the twelve months to Jun 30, 2026, up 13.9% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue is scaling, but margin gains have not reached profitability, while 2025 cash use and leverage made the financing structure more demanding.
The less visible deterioration is in cash conversion: operating cash flow worsened from-$18.0M in FY2024 to-$42.3M in FY2025 even as the net loss remained broadly similar. Rising receivables and inventory alongside that gap indicate that working capital absorbed cash as sales expanded, rather than growth translating cleanly into cash.
Revenue rose from
The balance sheet moved from near break-even equity in FY2024 to negative equity of
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Evolus, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Evolus, Inc. has an operating margin of -11.0%, meaning the company loses $11 on every $100 of revenue. This results in a profitability score of 26/100. This is up from -12.9% the prior year.
Evolus, Inc.'s revenue grew 11.6% year-over-year to $297.2M, a solid pace of expansion. This earns a growth score of 83/100.
Evolus, Inc.'s current ratio of 1.90 indicates adequate short-term liquidity, earning a score of 56/100. The company can meet its near-term obligations, though with limited headroom.
Evolus, Inc.'s operations used $42.3M of cash, and capex of $3.4M added to the outflow, for a free cash flow shortfall of $45.7M. This results in a cash flow score of 10/100.
Evolus, Inc. scores -1.69, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($500.0M) relative to total liabilities ($249.0M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Evolus, Inc. passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
Evolus, Inc. reported a net loss of $51.6M while operations used $42.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Evolus, Inc. reported an operating loss of $32.7M against $19.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Evolus, Inc. generated $84.1M in revenue in Q2 2026. This represents an increase of 21.2% from the same quarter a year earlier. Against the prior quarter it is up 15.0%.
Evolus, Inc.'s EBITDA was -$3.0M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 67.5% from the same quarter a year earlier. Against the prior quarter it is up 33.1%.
Evolus, Inc. reported -$8.1M in net income in Q2 2026. This represents an increase of 53.0% from the same quarter a year earlier. Against the prior quarter it is up 24.6%.
Evolus, Inc. earned -$0.12 per diluted share (EPS) in Q2 2026. This represents an increase of 55.6% from the same quarter a year earlier. Against the prior quarter it is up 25.0%.
Cash & Balance Sheet
Evolus, Inc. recorded an outflow of $3.6M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 85.7% from the same quarter a year earlier. Against the prior quarter it is up 64.9%.
Evolus, Inc. held $45.2M in cash against $156.7M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Evolus, Inc.'s gross margin was 68.0% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 2.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.1 percentage points.
Evolus, Inc.'s operating margin was -5.4% in Q2 2026, reflecting core business profitability. This is up 9.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 4.0 percentage points.
Evolus, Inc.'s net profit margin was -9.6% in Q2 2026, showing the share of revenue converted to profit. This is up 15.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 5.0 percentage points.
Not reported for Q2 2026.
Capital Allocation
Evolus, Inc. invested $1.9M in research and development in Q2 2026. This represents an increase of 3.0% from the same quarter a year earlier. Against the prior quarter it is down 15.5%.
Evolus, Inc. invested $50K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 92.7% from the same quarter a year earlier. Against the prior quarter it is down 88.0%.
Not reported for Q2 2026.
EOLS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $84.1M+21.2% | $73.1M+6.7% | $90.3M+14.4% | $69.0M+12.9% | $69.4M+3.7% | $68.5M+15.5% | $78.9M+29.4% | $61.1M+22.1% |
| Cost of Revenue | $26.9M+11.8% | $24.2M+10.9% | $31.0M+17.8% | $23.1M+21.8% | $24.1M+21.3% | $21.9M+16.1% | $26.3M+18.4% | $19.0M+23.0% |
| Gross Profit | $57.2M+26.2% | $48.9M+4.8% | $59.3M+12.6% | $45.8M+8.9% | $45.3M-3.7% | $46.7M+15.2% | $52.6M+35.7% | $42.1M+21.7% |
| R&D Expenses | $1.9M+3.0% | $2.2M+1.3% | $3.5M+43.3% | $2.0M-11.6% | $1.8M-21.8% | $2.2M+6.4% | $2.4M+2.1% | $2.3M+45.8% |
| SG&A Expenses | $57.1M+0.7% | $52.0M-8.2% | $54.7M+8.8% | $52.8M+0.6% | $56.7M+13.0% | $56.6M+25.5% | $50.2M+16.7% | $52.5M+21.2% |
| Operating Income | -$4.5M+55.5% | -$6.8M+54.9% | $4.2M+282.4% | -$11.5M+25.7% | -$10.2M-32.6% | -$15.2M-70.1% | -$2.3M+73.2% | -$15.5M-15.1% |
| EBITDA | -$3.0M+67.5% | -$4.5M+66.9% | $8.1M+960.4% | -$10.4M+28.0% | -$9.3M-47.9% | -$13.6M-81.1% | -$940K+87.1% | -$14.4M-18.6% |
| Interest Expense | $4.2M-42.1% | $4.0M-10.0% | $4.0M-13.0% | $4.1M-14.1% | $7.2M+53.5% | $4.4M-6.1% | $4.6M+12.2% | $4.8M+25.8% |
| Income Tax | -$154K-390.6% | $256K+255.6% | $385K-12.5% | $167K+24.6% | $53K+23.3% | $72K+53.2% | $440K+315.1% | $134K+458.3% |
| Net Income | -$8.1M+53.0% | -$10.7M+43.5% | $130K+101.9% | -$15.7M+17.9% | -$17.1M-51.0% | -$18.9M-44.1% | -$6.8M+42.6% | -$19.2M-13.3% |
| EPS (Basic) | -$0.12+55.6% | -$0.16+46.7% | $0.00+100.0% | -$0.24+20.0% | -$0.27-50.0% | -$0.30-36.4% | -$0.10+50.0% | -$0.300.0% |
| EPS (Diluted) | -$0.12+55.6% | -$0.16+46.7% | $0.00+100.0% | -$0.24+20.0% | -$0.27-50.0% | -$0.30-36.4% | -$0.10+50.0% | -$0.300.0% |
| Diluted Shares (Avg) | 66M+2.2% | 65M+2.3% | N/A | 65M+2.5% | 65M+2.9% | 64M+8.3% | N/A | 63M+10.7% |
EOLS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $248.0M+8.4% | $220.6M+3.4% | $225.9M-2.9% | $219.0M-4.6% | $228.8M-2.1% | $213.4M-5.7% | $232.6M+23.1% | $229.6M+36.7% |
| Current Assets | $167.5M+15.6% | $138.9M+5.5% | $142.9M-5.6% | $134.9M-10.3% | $145.0M-8.3% | $131.7M-12.3% | $151.3M+34.6% | $150.4M+63.4% |
| Cash & Equivalents | $45.2M-26.8% | $49.8M-26.7% | $53.8M-38.1% | $43.5M-48.8% | $61.7M-34.1% | $67.9M-30.0% | $87.0M+38.4% | $85.0M+119.8% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $40.9M+54.6% | $24.8M+147.3% | $27.0M+121.8% | $32.9M+120.7% | $26.5M+97.7% | $10.0M-13.2% | $12.2M+10.5% | $14.9M-15.5% |
| Accounts Receivable | $62.4M+30.8% | $52.2M+10.0% | $54.7M+14.7% | $50.4M+13.0% | $47.7M+10.6% | $47.5M+38.6% | $47.7M+56.2% | $44.6M+46.5% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $21.2M0.0% | $21.2M0.0% | $21.2M0.0% | $21.2M0.0% | $21.2M0.0% | $21.2M0.0% | $21.2M0.0% | $21.2M0.0% |
| Total Liabilities | $278.9M+12.7% | $249.4M+13.4% | $249.0M+9.7% | $247.8M+10.7% | $247.5M+15.4% | $220.0M+5.9% | $227.0M+8.3% | $223.7M+19.4% |
| Current Liabilities | $98.7M+54.9% | $68.0M+21.0% | $75.3M+19.6% | $66.7M+9.7% | $63.8M+17.8% | $56.2M+20.2% | $63.0M+30.4% | $60.8M+25.3% |
| Non-Current Liabilities | $180.2M-1.9% | $181.4M+10.8% | $173.7M+5.8% | $181.0M+11.1% | $183.7M+14.6% | $163.7M+1.7% | $164.1M+1.7% | $162.9M+17.4% |
| Long-Term Debt | $156.7M+7.7% | $156.4M+28.4% | $146.1M+20.2% | $145.8M+20.3% | $145.5M+20.3% | $121.8M+1.0% | $121.5M+1.0% | $121.2M+27.5% |
| Total Equity | -$30.9M-65.7% | -$28.8M-335.8% | -$23.1M-518.4% | -$28.8M-588.3% | -$18.7M-196.6% | -$6.6M-135.8% | $5.5M+126.7% | $5.9M+130.4% |
| Retained Earnings | -$679.8M-5.3% | -$671.7M-6.9% | -$661.0M-8.5% | -$661.2M-9.7% | -$645.4M-10.6% | -$628.3M-9.8% | -$609.4M-9.0% | -$602.6M-10.1% |
EOLS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.6M+85.5% | -$10.0M+36.3% | $12.8M+166.8% | -$14.7M-156.4% | -$24.8M-283.2% | -$15.6M-47.3% | $4.8M+491.4% | -$5.7M-519.3% |
| Depreciation & Amortization | $1.5M+64.1% | $2.3M+50.1% | $2.3M+64.0% | $1.1M+5.2% | $932K-34.7% | $1.6M+10.9% | $1.4M+0.1% | $1.1M-17.1% |
| Stock-Based Compensation | $5.6M+25.3% | $5.1M-13.7% | N/A | $5.1M-1.6% | $4.5M-22.4% | $5.9M+16.7% | N/A | $5.2M+13.6% |
| Capital Expenditures | $50K-92.7% | $415K+30.1% | $1.5M+237.7% | $955K+205.1% | $688K+48.0% | $319K+24.6% | $438K+109.6% | $313K+979.3% |
| Free Cash Flow | -$3.6M+85.7% | -$10.4M+35.0% | $11.3M+159.7% | -$15.6M-158.9% | -$25.5M-267.4% | -$16.0M-46.7% | $4.4M+623.5% | -$6.0M-533.3% |
| Investing Cash Flow | -$500K+77.9% | -$1.7M+9.1% | -$2.2M-59.0% | -$2.2M-53.0% | -$2.3M-80.8% | -$1.9M-133.5% | -$1.4M-277.3% | -$1.4M-161.6% |
| Financing Cash Flow | -$365K-101.8% | $7.6M+567.1% | $77K+105.9% | -$1.8M-25.1% | $20.7M+361.1% | -$1.6M-103.6% | -$1.3M-105.6% | -$1.4M+0.2% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
EOLS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 68.0%+2.7pp | 66.9%-1.2pp | 65.7%-1.0pp | 66.5%-2.5pp | 65.3%-5.0pp | 68.1%-0.2pp | 66.7%+3.1pp | 68.9%-0.2pp |
| Operating Margin | -5.4%+9.3pp | -9.4%+12.8pp | 4.7%+7.6pp | -16.7%+8.7pp | -14.7%-3.2pp | -22.1%-7.1pp | -2.9%+11.2pp | -25.3%+1.5pp |
| Net Margin | -9.6%+15.1pp | -14.6%+13.0pp | 0.1%+8.7pp | -22.8%+8.6pp | -24.7%-7.7pp | -27.6%-5.5pp | -8.6%+10.8pp | -31.4%+2.4pp |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | -123.0% | -325.5% |
| Return on Assets | -3.3%+4.2pp | -4.8%+4.0pp | 0.1%+3.0pp | -7.2%+1.2pp | -7.5%-2.6pp | -8.8%-3.0pp | -2.9%+3.3pp | -8.3%+1.7pp |
| Current Ratio | 1.70-0.6x | 2.04-0.3x | 1.90-0.5x | 2.02-0.5x | 2.27-0.6x | 2.34-0.9x | 2.40+0.1x | 2.47+0.6x |
| Debt-to-Equity | N/A | N/A | N/A | N/A | N/A | N/A | 22.00 | 20.58 |
| Asset Turnover | 0.340.0x | 0.330.0x | 0.40+0.1x | 0.310.0x | 0.300.0x | 0.32+0.1x | 0.340.0x | 0.270.0x |
| FCF Margin | -4.3%+32.4pp | -14.2%+9.1pp | 12.6%+7.0pp | -22.7%-12.8pp | -36.7%-26.4pp | -23.3%-5.0pp | 5.5%+4.5pp | -9.9%-8.0pp |
Note: Shareholder equity is negative (-$23.1M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Evolus, Inc. EOLS | FY2025 | $297.2M | -$51.6M | -17.4% | $500.0M | 34/100 |
| Canopy Growth Corporation CGC | FY2026 | N/A | -$189.0M | N/A | $311.1M | — |
| Eton Pharmaceutcials, Inc. ETON | FY2025 | $80.0M | -$4.6M | -5.8% | $1.5B | 51/100 |
| Emergent Biosolutions, Inc. EBS | FY2025 | $742.9M | $52.6M | 7.1% | $368.1M | 36/100 |
| Kamada Ltd KMDA | FY2025 | $180.5M | $20.2M | 11.2% | $451.9M | 41/100 |
| Esperion Therapeutics, Inc. ESPR | FY2025 | $403.1M | -$22.7M | -5.6% | $819.5M | 30/100 |
Where Evolus, Inc. Ranks
Frequently Asked Questions
What is Evolus, Inc.'s annual revenue?
Evolus, Inc. (EOLS) reported $297.2M in total revenue for fiscal year 2025. This represents a 11.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Evolus, Inc.'s revenue growing?
Evolus, Inc. (EOLS) revenue grew by 11.6% year-over-year, from $266.3M to $297.2M in fiscal year 2025.
Is Evolus, Inc. profitable?
No, Evolus, Inc. (EOLS) reported a net income of -$51.6M in fiscal year 2025, with a net profit margin of -17.4%.
What is Evolus, Inc.'s EBITDA?
Evolus, Inc. (EOLS) had EBITDA of -$25.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Evolus, Inc. have?
As of fiscal year 2025, Evolus, Inc. (EOLS) had $53.8M in cash and equivalents against $146.1M in long-term debt.
What is Evolus, Inc.'s gross margin?
Evolus, Inc. (EOLS) had a gross margin of 66.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Evolus, Inc.'s operating margin?
Evolus, Inc. (EOLS) had an operating margin of -11.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Evolus, Inc.'s net profit margin?
Evolus, Inc. (EOLS) had a net profit margin of -17.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Evolus, Inc.'s free cash flow?
Evolus, Inc. (EOLS) recorded an outflow of $45.7M in free cash flow during fiscal year 2025. This represents a -134.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Evolus, Inc.'s operating cash flow?
Evolus, Inc. (EOLS) recorded an outflow of $42.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Evolus, Inc.'s total assets?
Evolus, Inc. (EOLS) had $225.9M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Evolus, Inc.'s capital expenditures?
Evolus, Inc. (EOLS) invested $3.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Evolus, Inc. spend on research and development?
Evolus, Inc. (EOLS) invested $9.6M in research and development during fiscal year 2025.
What is Evolus, Inc.'s current ratio?
Evolus, Inc. (EOLS) had a current ratio of 1.90 as of fiscal year 2025, which is generally considered healthy.
What is Evolus, Inc.'s return on assets (ROA)?
Evolus, Inc. (EOLS) had a return on assets of -22.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Evolus, Inc.'s P/E ratio?
Evolus, Inc. (EOLS) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $500.0M as of Oct 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Evolus, Inc.'s price-to-sales ratio?
Evolus, Inc. (EOLS) trades at 1.6x sales, its market capitalization divided by revenue of $316.5M revenue, trailing 12 months to June 30, 2026. The market capitalization is $500.0M as of Oct 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Evolus, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Evolus, Inc. (EOLS) held $53.8M in cash, cash equivalents and investments, and reported an operating cash outflow of $42.3M over that year. Dividing the one by the other, the reported balance equals about 15 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is Evolus, Inc.'s debt-to-equity ratio negative or not reported?
Evolus, Inc. (EOLS) has negative shareholder equity of -$23.1M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Evolus, Inc.'s Altman Z-Score?
Evolus, Inc. (EOLS) has an Altman Z-Score of -1.69, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Evolus, Inc.'s Piotroski F-Score?
Evolus, Inc. (EOLS) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Evolus, Inc.'s earnings high quality?
Evolus, Inc. (EOLS) reported a net loss of $51.6M while operations used $42.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Evolus, Inc. cover its interest payments?
Evolus, Inc. (EOLS) reported an operating loss of $32.7M against $19.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Evolus, Inc.?
Evolus, Inc. (EOLS) scores 34 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.